Bicara Therapeutics (NASDAQ:BCAX) Stock Rating Reaffirmed as "Buy" by BTIG Research

Key Points

• BTIG Research reaffirmed its “Buy” rating on Bicara Therapeutics and set a $39 price target, implying approximately 132% upside from the stock’s $16.78 opening price.
• Analyst sentiment is broadly positive, with Bicara receiving a “Moderate Buy” consensus rating and an average price target of $32.64; the company recently met quarterly EPS expectations at a loss of $0.82 per share.
• Company insiders sold shares under pre-arranged Rule 10b5-1 plans, including sales by the CEO and CFO; insiders have sold 58,750 shares worth about $1.55 million over the past 90 days.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They currently have a $39.00 target price on the stock. BTIG Research's target price would suggest a potential upside of 132.42% from the stock's current price.

A number of other equities research analysts also recently commented on the stock. Citigroup reissued a "market outperform" rating on shares of Bicara Therapeutics in a research report on Friday, August 21st. Wedbush boosted their target price on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 12th. Mizuho increased their target price on Bicara Therapeutics from $18.00 to $20.00 and gave the company a "neutral" rating in a report on Wednesday, August 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Bicara Therapeutics in a research note on Thursday, September 10th. Finally, BMO Capital Markets started coverage on Bicara Therapeutics in a report on Tuesday, August 18th. They set an "outperform" rating and a $35.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bicara Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $32.64.

Bicara Therapeutics Price Performance

BCAX stock opened at $16.78 on Monday. The business's 50-day moving average is $21.66 and its two-hundred day moving average is $23.15. The firm has a market capitalization of $1.11 billion, a P/E ratio of -5.41 and a beta of -0.70. Bicara Therapeutics has a 1 year low of $13.70 and a 1 year high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting analysts' consensus estimates of ($0.82). On average, analysts expect that Bicara Therapeutics will post -3.49 EPS for the current year.

Insider Transactions at Bicara Therapeutics

In other news, CFO Ivan Hyep sold 12,500 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $27.97, for a total value of $349,625.00. Following the completion of the sale, the chief financial officer directly owned 129,855 shares of the company's stock, valued at approximately $3,632,044.35. The trade was a 8.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $279,800.00. Following the completion of the sale, the chief executive officer directly owned 362,152 shares of the company's stock, valued at approximately $10,133,012.96. This trade represents a 2.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 58,750 shares of company stock worth $1,554,800. Corporate insiders own 13.80% of the company's stock.

Institutional Investors Weigh In On Bicara Therapeutics

Large investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd increased its holdings in shares of Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock valued at $97,000 after acquiring an additional 4,585 shares during the period. Arizona State Retirement System purchased a new stake in Bicara Therapeutics in the 2nd quarter valued at $241,000. Susquehanna Fundamental Investments LLC acquired a new stake in Bicara Therapeutics during the 2nd quarter worth $272,000. ADAR1 Capital Management LLC purchased a new position in Bicara Therapeutics during the 2nd quarter worth $407,000. Finally, Engineers Gate Manager LP purchased a new position in Bicara Therapeutics during the 2nd quarter worth $499,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc NASDAQ: BCAX is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company's approach is designed to address both cancer cells and the tumor microenvironment, which can suppress immune responses and limit the effectiveness of existing treatments.

Bicara's lead product candidate is ficerafusp alfa, also known as BCA101. It is an investigational bifunctional fusion protein designed to target the epidermal growth factor receptor (EGFR) on tumor cells while blocking transforming growth factor beta (TGF-β), a signaling pathway associated with tumor growth and immune suppression.